XBiotech Inc (XBIT):企業の財務・戦略的SWOT分析

◆英語タイトル:XBiotech Inc (XBIT) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH2540713FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥68,400見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥102,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
XBiotech Inc (XBiotech) is a biopharmaceutical company that discovers, develops and commercialize therapeutic antibodies based proprietary technology. The company offers monoclonal antibodies treatment for various diseases. It’s lead product Xilonix, a therapeutic antibody being developed for the treatment of metastatic colorectal cancer. XBiotech offers clinical trial activity services, oncology, MRSA, and dermatology related solutions. The company develops a True Human technology to discover and develop targeted antibody candidates. It pipeline includes candidates, which target various therapeutic areas such as pyoderma gangrenosum, plaque psoriasis, influenza and Type II diabetes, among others. It has operations in the US, Switzerland, Japan and Germany. XBiotech is headquartered in Austin, Texas, the US.

XBiotech Inc Key Recent Developments

Jan 19,2021: XBiotech announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy
Sep 21,2020: XBiotech developing true human antibody combination as candidate treatment for influenza-COVID-19 co-infections
Jul 22,2020: XBiotech achieves milestone for production of its new potential blockbuster Anti-IL-1? therapy
Jul 14,2020: XBiotech announces discovery that blocking Interleukin-1a reduces brain injury and neurological deficit after stroke
May 01,2020: XBiotech identifies “Super Bloods” for the development of a True Human COVID-19 Therapy

This comprehensive SWOT profile of XBiotech Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of XBiotech Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

XBiotech Inc – Key Information
XBiotech Inc – Overview
XBiotech Inc – Key Employees
XBiotech Inc – Key Employee Biographies
XBiotech Inc – Key Operational Heads
XBiotech Inc – Major Products and Services
XBiotech Inc – History
XBiotech Inc – Company Statement
XBiotech Inc – Locations And Subsidiaries
XBiotech Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

XBiotech Inc – Business Description
XBiotech Inc – Corporate Strategy
XBiotech Inc – SWOT Analysis
SWOT Analysis – Overview
XBiotech Inc – Strengths
XBiotech Inc – Weaknesses
XBiotech Inc – Opportunities
XBiotech Inc – Threats
XBiotech Inc – Key Competitors

Section 3 – Company Financial Performance Charts

XBiotech Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

XBiotech Inc, Key Information
XBiotech Inc, Key Ratios
XBiotech Inc, Share Data
XBiotech Inc, Major Products and Services
XBiotech Inc, History
XBiotech Inc, Key Employees
XBiotech Inc, Key Employee Biographies
XBiotech Inc, Key Operational Heads
XBiotech Inc, Other Locations
XBiotech Inc, Subsidiaries
XBiotech Inc, Key Competitors
XBiotech Inc, SWOT Analysis
XBiotech Inc, Ratios based on current share price
XBiotech Inc, Annual Ratios
XBiotech Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[XBiotech Inc (XBIT):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • De La Rue Plc (DLAR):企業の財務・戦略的SWOT分析
    De La Rue Plc (DLAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Arab Bank (Switzerland) Ltd.:企業の戦略・SWOT・財務情報
    Arab Bank (Switzerland) Ltd. - Strategy, SWOT and Corporate Finance Report Summary Arab Bank (Switzerland) Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Oglethorpe Power Corp:企業の戦略的SWOT分析
    Oglethorpe Power Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Loral Space & Communications Inc (LORL):企業の財務・戦略的SWOT分析
    Loral Space & Communications Inc (LORL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Oncology Venture ApS-製薬・医療分野:企業M&A・提携分析
    Summary Oncology Venture ApS (Oncology Venture), a subsidiary of Oncology Venture Sweden AB is a drug development company that discovers new oncology products, and rescuing failed ones. The company provides gene-tumor-technology for identifying patients with resistance to anticancer drug. Its activi …
  • Kaneka Corp (4118):企業の財務・戦略的SWOT分析
    Kaneka Corp (4118) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Mahaweli Reach Hotels Plc:企業の戦略・SWOT・財務分析
    Mahaweli Reach Hotels Plc - Strategy, SWOT and Corporate Finance Report Summary Mahaweli Reach Hotels Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Alliqua BioMedical Inc (ALQA)-医療機器分野:企業M&A・提携分析
    Summary Alliqua BioMedical Inc (Alliqua BioMedical), formerly HepaLife Technologies Inc is a regenerative technology company that builds a suite of regenerative solutions for wound and tissue repair. The company’s product categories include ultrasound healing therapy, human biologics, antimicrobial …
  • Citibank Berhad:企業の戦略的SWOT分析
    Citibank Berhad - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Polo Resources Ltd (POL):石油・ガス:M&Aディール及び事業提携情報
    Summary Polo Resources Ltd (Polo Resources) is a natural resource and mine development investment company that evaluates, acquires, and develops substantial investments in companies and projects. The company also invests in exploration companies. It invests in the gold, oil and gas, coal, phosphate, …
  • CITIC Resources Holdings Limited:企業の戦略・SWOT・財務情報
    CITIC Resources Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary CITIC Resources Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Rubicon Genomics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Rubicon Genomics Inc (Rubicon Genomics), a subsidiary of the Takara Bio Group is a provider of pre-analytical amplification technologies. The company offers various types of kits for whole genome sequencing (WGS), whole exome sequencing (WES), targeted sequencing, copy number variation (CNV) …
  • Assam Company India Ltd (ASSAMCO):企業の財務・戦略的SWOT分析
    Assam Company India Ltd (ASSAMCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Oversea-Chinese Banking Corp Ltd:企業の戦略・SWOT・財務情報
    Oversea-Chinese Banking Corp Ltd - Strategy, SWOT and Corporate Finance Report Summary Oversea-Chinese Banking Corp Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Harvard Bioscience Inc (HBIO):医療機器:M&Aディール及び事業提携情報
    Summary Harvard Bioscience Inc (Harvard Bioscience) develops, manufactures and markets scientific instruments systems and lab consumables. The company’s product portfolio encompasses physiology, cell, molecular instruments products; electrophysiology products; and laboratory products and supplies. I …
  • ERI Bancaire SA:企業の戦略的SWOT分析
    ERI Bancaire SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Helix BioMedix Inc-製薬・医療分野:企業M&A・提携分析
    Summary Helix BioMedix Inc (Helix) is a dermatology and consumer skin care products company. It develops an extensive proprietary library of structurally diverse bioactive peptides for the applications in consumer skin care products and prescription products. Its peptides are used in cosmeceuticals, …
  • SGL Carbon SE:企業の戦略・SWOT・財務分析
    SGL Carbon SE - Strategy, SWOT and Corporate Finance Report Summary SGL Carbon SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Nabriva Therapeutics plc (NBRV):企業の財務・戦略的SWOT分析
    Summary Nabriva Therapeutics Plc (Nabriva) is a biopharmaceutical company that researches and develops antibiotics for the treatment of infections. The company offers product candidate such as Xenleta (lefamulin), CONTEPO (fosfomycin), being developed in both intravenous and oral formulations for th …
  • CS Wind Corp (112610):企業の財務・戦略的SWOT分析
    Summary CS Wind Corp (CS Wind) formerly Choong San Corp, is a global wind tower company that manufactures and distributes aluminum platforms used for wind power generation towers. The company’s products include transition piece, wind tower, tower internal parts, oil and gas pipes, and plant equipmen …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆